Trial ID or NCT#

NCT00632853

Status

RECRUITING

Purpose

Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as etoposide, carboplatin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which radiation therapy regimen is more effective when given together with chemotherapy in treating patients with limited-stage small cell lung cancer. This randomized phase III trial is comparing different chest radiation therapy regimens to see how well they work in treating patients with limited-stage small cell lung cancer.

Official Title

Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

A. Dimitrios Colevas
Medical oncologist, Head and neck specialist, Cutaneous oncology specialist
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head and Neck Surgery at the Stanford University Medical Center
Heather Wakelee
Medical oncologist, Thoracic specialist
Professor of Medicine (Oncology) at the Stanford University Medical Center
Billy W. Loo, Jr., MD, PhD, DABR
Radiation oncologist, Thoracic specialist
Professor of Radiation Oncology (Radiation Therapy) at the Stanford University Medical Center
Joseph Shrager
Thoracic surgeon, Surgical oncologist
Professor of Cardiothoracic Surgery at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Manpreet Kaur Bedi
(650) 723-3110